Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Immunome financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$12.2
2024-10-29
Market Capitalization
$746.5 M
2024-10-28
Revenue
$14 M
FY, 2023
CreditSafe Score
?
Score changed on Jan 24, 2025
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 |
|---|---|---|---|---|---|---|
| Revenue | 14.0M | |||||
| General and administrative expense | 866.0K | 1.5M | 4.8M | 11.1M | 13.6M | 19.7M |
| Operating expense total | 7.7M | 10.3M | 12.3M | 36.9M | 42.7M | |
| EBIT | (7.7M) | (10.3M) | (12.3M) | (25.2M) | (36.9M) | (109.5M) |
| EBIT margin, % | -781.4% | |||||
| Interest expense | 102.0K | 96.0K | 38.0K | (10.0K) | 5.0K | 2.7M |
| Net Income | (7.8M) | (10.4M) | (17.8M) | (24.7M) | (36.9M) | (106.8M) |
| EPS | (1.2) | (1.6) | (3.1) | (5.4) |